Thierry Philip
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thierry Philip has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
P Biron
15 shared publicationsM Brunat-Mentigny
13 shared publicationsE Bouffet
11 shared publications- Didier Frappaz
Centre Léon Bérard, Lyon, France
9 shared publications F Chauvin
8 shared publicationsI Philip
8 shared publications
Latest Publications
- 1 November 2015
- Published by Elsevier in Value in Health
- Vol. 18 (7) , A485
Cost of Questionnaire-Based Process to Identify Occupational Exposures Among Patients with Lung Cancer
- 1 November 2015
- Published by Elsevier in Value in Health
- Vol. 18 (7) , A485
Cost of Questionnaire-Based Process to Identify Occupational Exposures Among Patients with Lung Cancer
- 1 September 2002
- Vol. 50 (4) , 393-403
[Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France].
The purpose of this study was to determine to what extent methods used to assess health cost affect the total cost of a therapeutic procedure. We assessed total cost of 160 consecutive therapeutic intensification procedures using autologous blood progenitor cell transplantation, 95 for lymphoma and 65 for breast tumor. The average total cost of the therapeutic intensification for patients with lymphoma was 227156 francs (34630 euros), including 60720 francs (9257 euros) for mobilization, 14947 francs (22402 euros) for the treatment period and 19489 francs (2971 euros) for secondary hospitalization. The average total cost for patients with a breast tumor was 199626 francs (30433 euros), including 39269 francs (5987 euros) for mobilization, 14912 francs (22737 euros) for the treatment period, and 11215 francs (1709 euros) for secondary hospitalization. We compared our findings with those from six earlier French studies. Differences in the methodologies used focuses attention on the need for incentives for better harmonization of health cost assessment.
- 1 September 2002
- Vol. 50 (4) , 393-403
[Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France].
The purpose of this study was to determine to what extent methods used to assess health cost affect the total cost of a therapeutic procedure. We assessed total cost of 160 consecutive therapeutic intensification procedures using autologous blood progenitor cell transplantation, 95 for lymphoma and 65 for breast tumor. The average total cost of the therapeutic intensification for patients with lymphoma was 227156 francs (34630 euros), including 60720 francs (9257 euros) for mobilization, 14947 francs (22402 euros) for the treatment period and 19489 francs (2971 euros) for secondary hospitalization. The average total cost for patients with a breast tumor was 199626 francs (30433 euros), including 39269 francs (5987 euros) for mobilization, 14912 francs (22737 euros) for the treatment period, and 11215 francs (1709 euros) for secondary hospitalization. We compared our findings with those from six earlier French studies. Differences in the methodologies used focuses attention on the need for incentives for better harmonization of health cost assessment.
- 1 February 2002
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 41 (2) , 213-223
High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma
- 1 February 2002
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 41 (2) , 213-223
High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma
- 1 December 2001
- Vol. 88 (12) , 1222-7
[School reinsertion of children treated for tumors of the brain: experience of the Léon-Bérard center].
School integration of children with brain tumor is part of the quality of their life. It may also become a nightmare both for the child and for the teacher when no recommendation has been addressed to the latter. In France, official recommendations allow the meeting and information exchanges in the school between teachers and all the people who take care medically of the child. We report our experience in Centre Léon-Bérard of Lyon, concerning 38 children with brain tumors (102 meetings). Though difficult to assess scientifically, the benefit from these meetings is obvious. For the teachers: the knowledge and understanding of the physiopathology of brain tumors and secondary sequellae facilitates teaching. For the child: the disappearance of surrounding fears and fantasms make life easier. This experience is so rich that it should be extended to other pathologies.
- 1 December 2001
- Vol. 88 (12) , 1222-7
[School reinsertion of children treated for tumors of the brain: experience of the Léon-Bérard center].
School integration of children with brain tumor is part of the quality of their life. It may also become a nightmare both for the child and for the teacher when no recommendation has been addressed to the latter. In France, official recommendations allow the meeting and information exchanges in the school between teachers and all the people who take care medically of the child. We report our experience in Centre Léon-Bérard of Lyon, concerning 38 children with brain tumors (102 meetings). Though difficult to assess scientifically, the benefit from these meetings is obvious. For the teachers: the knowledge and understanding of the physiopathology of brain tumors and secondary sequellae facilitates teaching. For the child: the disappearance of surrounding fears and fantasms make life easier. This experience is so rich that it should be extended to other pathologies.
- 1 November 2001
- Vol. 88 (11) , 1129-35
[Metastatic osteosarcoma: prognosis factors and treatment].
Long term outcome and prognosis factors of patients with metastatic osteosarcoma were evaluated on 29 observations from 3 centres reviewed retrospectively. Twenty-nine patients less than 18 years old were treated from 1990 to 1998. Only 29 of these patients had received similar treatments associating chemotherapy and surgery, adapted according to histological and clinical response to treatment, as recommended by the SFOP. Overall survival at five years was 26%, and disease free survival 14%. Eight patients are alive, four in first complete remission (CR) and four in second CR. Three of the four patients alive in first CR had bone metastases at diagnosis. On univariate analysis, factors predicting survival are: the numbers of organs affected by metastatic lesions, the number of lung nodules and the type of surgery. This is, to our knowledge, the first report of long term survivors with bone metastases at diagnosis. Metastatic osteosarcoma prognosis remain poor. A randomised study would help to define the best possible treatment for this disease.
- 1 November 2001
- Vol. 88 (11) , 1129-35
[Metastatic osteosarcoma: prognosis factors and treatment].
Long term outcome and prognosis factors of patients with metastatic osteosarcoma were evaluated on 29 observations from 3 centres reviewed retrospectively. Twenty-nine patients less than 18 years old were treated from 1990 to 1998. Only 29 of these patients had received similar treatments associating chemotherapy and surgery, adapted according to histological and clinical response to treatment, as recommended by the SFOP. Overall survival at five years was 26%, and disease free survival 14%. Eight patients are alive, four in first complete remission (CR) and four in second CR. Three of the four patients alive in first CR had bone metastases at diagnosis. On univariate analysis, factors predicting survival are: the numbers of organs affected by metastatic lesions, the number of lung nodules and the type of surgery. This is, to our knowledge, the first report of long term survivors with bone metastases at diagnosis. Metastatic osteosarcoma prognosis remain poor. A randomised study would help to define the best possible treatment for this disease.
- 1 March 2001
- Vol. 88 (3) , 321-8
[Coordinated organization of symptoms management and support in all the stages of cancer disease: putting in place pluridisciplinary structures of supportive oncological care].
The organization of the management of pain and other symptoms all along the cancer disease, of psychological support and palliative care is a complex question that does not correspond to any perfectly established model, both in France and abroad. Different structures are implied in there care and coexist with an insufficient coordination: cancerology structures, structures of chronic pain management, structures of psycho-oncology, structures of palliative care. Some other assistances are more or less isolated inside the hospital: nutritional support, social assistance, action against tobacco and other addictions, volunteer work. Because of the evolution of practices and mentalities over the last ten years, the highlights of evident interfaces and complementary activities, the notions of "continuous care" and "integrated care" inside conventional departments, the budgetary and organizational restraints, it is now possible to propose a model of hospital structure adapted to the problem of supportive care. The creation is proposed from preexisting structures, consultations, units, departments of supportive oncological care according to the size of the institution. The structure should comply with some specifications, sometimes regulations, and to coordinate at best different competencies in the interest of the patients and medical teams : pain and symptoms management (of which palliative care is an important part), psycho-oncology, rehabilitation (functional rehabilitation, nutrition, social work, fights against addictions). A pooling of technology settings is one of its interest. The model can be applied in other domains than cancerology and in most health institutions.
- 1 March 2001
- Vol. 88 (3) , 321-8
[Coordinated organization of symptoms management and support in all the stages of cancer disease: putting in place pluridisciplinary structures of supportive oncological care].
The organization of the management of pain and other symptoms all along the cancer disease, of psychological support and palliative care is a complex question that does not correspond to any perfectly established model, both in France and abroad. Different structures are implied in there care and coexist with an insufficient coordination: cancerology structures, structures of chronic pain management, structures of psycho-oncology, structures of palliative care. Some other assistances are more or less isolated inside the hospital: nutritional support, social assistance, action against tobacco and other addictions, volunteer work. Because of the evolution of practices and mentalities over the last ten years, the highlights of evident interfaces and complementary activities, the notions of "continuous care" and "integrated care" inside conventional departments, the budgetary and organizational restraints, it is now possible to propose a model of hospital structure adapted to the problem of supportive care. The creation is proposed from preexisting structures, consultations, units, departments of supportive oncological care according to the size of the institution. The structure should comply with some specifications, sometimes regulations, and to coordinate at best different competencies in the interest of the patients and medical teams : pain and symptoms management (of which palliative care is an important part), psycho-oncology, rehabilitation (functional rehabilitation, nutrition, social work, fights against addictions). A pooling of technology settings is one of its interest. The model can be applied in other domains than cancerology and in most health institutions.
- 25 November 2000
- Vol. 29 (36) , 2004-8
[Standards, options, and recommendations for the use of hematopoietic growth factors in oncology].
Four hematopoietic growth factors have marketing approval in France: filgrastime (G-CSF), malgraostime (GM-CSF), lenograstime (glycolysated G-CSF) and erythropoietin. A standards, options and recommendations document has not yet been established for erythropoietin which is excluded from this report. Administration of hematopoietic growth factors can be proposed in five clinical situations: primary prophylaxis, secondary prophylaxis, curative care, after myeloablative chemotherapy and hematopoietic stem cell grafting, and finally mobilization of peripheral stem cells. Primary prophylaxis: excepting therapeutic trials, the use of hematopoietic growth factors is recommended for clinical situations where a significant incidence of neutropenia with fever has been reported in randomized trials and in rare cases where there is an increased risk of severe infectious complications. Hematopoietic growth factors are indispensable for increasing the quality of cytapheresis peripheral stem cell harvesting.
- 25 November 2000
- Vol. 29 (36) , 2004-8
[Standards, options, and recommendations for the use of hematopoietic growth factors in oncology].
Four hematopoietic growth factors have marketing approval in France: filgrastime (G-CSF), malgraostime (GM-CSF), lenograstime (glycolysated G-CSF) and erythropoietin. A standards, options and recommendations document has not yet been established for erythropoietin which is excluded from this report. Administration of hematopoietic growth factors can be proposed in five clinical situations: primary prophylaxis, secondary prophylaxis, curative care, after myeloablative chemotherapy and hematopoietic stem cell grafting, and finally mobilization of peripheral stem cells. Primary prophylaxis: excepting therapeutic trials, the use of hematopoietic growth factors is recommended for clinical situations where a significant incidence of neutropenia with fever has been reported in randomized trials and in rare cases where there is an increased risk of severe infectious complications. Hematopoietic growth factors are indispensable for increasing the quality of cytapheresis peripheral stem cell harvesting.
- 1 September 2000
- Vol. 87 (9) , 671-9
[Huriet law: application in a regional cancer centre (Centre Léon-Bérard, Lyon)].
Clinical research is one of the main activities in cancer centres and is submitted in France to a specific law (named "loi Huriet") which includes good clinical practices. We are now conducting a general program of quality evaluation and improvement in the regional cancer centre of Lyon (centre Léon-Bérard). Part of this program is an audit of the application of the Huriet law. Since no instrument exist for measuring this application, we have created a specific one, that attribute notation according to the different aspects of the law. Results show a good level of conformity but sometime non sufficient. There is no difference between the two studied years. Quality changes according to promoters (private or academic) and monitoring. Written procedures and specific training for the different actors are required to improve quality of clinical research with focus on the patient interest.
- 1 September 2000
- Vol. 87 (9) , 671-9
[Huriet law: application in a regional cancer centre (Centre Léon-Bérard, Lyon)].
Clinical research is one of the main activities in cancer centres and is submitted in France to a specific law (named "loi Huriet") which includes good clinical practices. We are now conducting a general program of quality evaluation and improvement in the regional cancer centre of Lyon (centre Léon-Bérard). Part of this program is an audit of the application of the Huriet law. Since no instrument exist for measuring this application, we have created a specific one, that attribute notation according to the different aspects of the law. Results show a good level of conformity but sometime non sufficient. There is no difference between the two studied years. Quality changes according to promoters (private or academic) and monitoring. Written procedures and specific training for the different actors are required to improve quality of clinical research with focus on the patient interest.
- Open Access
- 1 September 1999
- Published by Elsevier in Annals of Oncology
- Vol. 10 (9) , 1065-1072
High-dose methotrexate and HELP [Holoxan (ifosfamide), Eldesine (vindesine), platinum] - doxorubicin in non-metastatic osteosarcoma of the extremity: A French multicentre pilot study
- 1 September 1999
- Published by Elsevier in Annals of Oncology
- Vol. 10 (9) , 1065-1072
Open AccessHigh-dose methotrexate and HELP [Holoxan (ifosfamide), Eldesine (vindesine), platinum] - doxorubicin in non-metastatic osteosarcoma of the extremity: A French multicentre pilot study